Plus   Neg

Seres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results

Seres Therapeutics Inc. (MCRB) reported results from its Phase 1b study of SER-287 in patients with mild-to-moderate Ulcerative Colitis.

Seres Therapeutics gapped open lower Monday and declined during the first 45 minutes of trade. The stock was range-bound for the rest of the session and closed down by 3.74 at $12.30 with volume at over a 6-month high. Seres Therapeutics fell to a 2-month low and dropped below its 50-day moving average.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT